Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

LuPARP : 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer

Male<br/>OnlyGender Male

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Prostate<br/>CancersCancer LocationProstate

Systemic therapy | Urinary systemProstate

Trial Overview Read MoreRead more

This phase I trial is evaluating the combination of an oral therapy (olaparib) and a combination therapy (177Lu-PSMA) in patients with castration resistant prostate cancer that has spread to other parts of the body and progressed on other targeted treatments.

This trial is treating patients with castration resistant prostate cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer

Other Non-Commercial Sponsor

Peter MacCallum Cancer Centre


To be eligible for this trial, patients must have metastatic castration resistant prostate cancer (mCRPC) that has progressed with a novel AR targeted agent (abiraterone and/or enzalutamide and/or apalutamide) and has not previously been exposed to platinums, PARP inhibitors or 177Lu-PSMA. Patients can have had prior exposure to docetaxel in the chemotherapy naïve setting or castrate setting. Eligible patients will be enrolled in the trial in two stages: a dose escalation and expansion stage. Depending on the stage of enrolment, patients will receive either escalating or fixed 7.4 GBq of 177Lu-PSMA every 6 weeks together with olaparib on days 2-15 of each cycle. A cycle is 42 days long. Patients will receive up to 4 cycles of treatment.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Richelle Linklater

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.